Pfizer Inc. $PFE Shares Bought by Martingale Asset Management L P

Key Points

• Martingale Asset Management L P increased its holdings in Pfizer Inc. by 313.1%, owning 525,188 shares valued at approximately $13.3 million after purchasing an additional 398,059 shares.
• Pfizer experienced a strong financial performance for the quarter, reporting $0.78 earnings per share and $14.65 billion in revenue, exceeding analysts' estimates.
• The company declared a quarterly dividend of $0.43 per share, resulting in an annualized dividend yield of 6.8%.

Martingale Asset Management L P boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 313.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 525,188 shares of the biopharmaceutical company's stock after purchasing an additional 398,059 shares during the period. Martingale Asset Management L P's holdings in Pfizer were worth $13,308,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Pacer Advisors Inc. lifted its position in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after acquiring an additional 17,957,928 shares during the last quarter. Nuveen LLC acquired a new position in shares of Pfizer in the 1st quarter worth $389,861,000. Starboard Value LP purchased a new stake in shares of Pfizer during the fourth quarter valued at $407,730,000. Goldman Sachs Group Inc. boosted its position in shares of Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after purchasing an additional 9,041,990 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after purchasing an additional 7,581,030 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.2%

NYSE:PFE opened at $25.3750 on Thursday. The company has a market capitalization of $144.27 billion, a P/E ratio of 13.50, a P/E/G ratio of 0.90 and a beta of 0.52. The stock's 50 day moving average price is $24.66 and its 200 day moving average price is $24.42. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm earned $0.60 EPS. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer's payout ratio is currently 91.49%.

Analysts Set New Price Targets

A number of analysts have commented on the stock. The Goldman Sachs Group upped their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Redburn Atlantic cut their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Jefferies Financial Group raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Wolfe Research lifted their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 30th. Finally, UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.